A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome

European Neuropsychopharmacology

Volumn 20, Issue 2, 2010, Pages 96-111

  Szego, Éva M ^a,b   Janáky, Tamás ^b   Szabó, Zoltán ^b   Csorba, Attila ^b   Kompagne, Hajnalka ^c   Müller, Géza ^c   Lévay, György ^c   Simor, Attila ^a,b   Juhász, Gábor ^a   Kékesi, Katalin A ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Anxiety; Drug discovery; Molecular characterization; Mouse model; Protein interaction networks; Proteomics

Indexed keywords

ENDOPEPTIDASE LA; ENOLASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMATE DEHYDROGENASE; LACTATE DEHYDROGENASE; LACTOYLGLUTATHIONE LYASE; MALATE DEHYDROGENASE; NEUROLYSIN; PHOSPHOGLYCERATE MUTASE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; PYRUVATE DEHYDROGENASE; PYRUVATE KINASE; SUCCINATE DEHYDROGENASE; SYNAPSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BRAIN; CONTROLLED STUDY; DEPRESSION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; SOCIAL PSYCHOLOGY; UNINDEXED SEQUENCE;

ANIMALS; ANXIETY; BRAIN; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; HYBRIDIZATION, GENETIC; MAZE LEARNING; MICE; MICE, INBRED STRAINS; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; PROTEOME; SPECIES SPECIFICITY;

EID: 73549110516     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.11.003     Document Type: Article

References (74)

1. Abi-Dargham A., Charney D.S., and Krystal J.H. Benzodiazepin receptor antagonists. Possible uses in treatment of neuropsychiatric disorders. CNS Drugs 8 (1997) 244-256
2. Ackermann T.F., Hörtnagl H., Wolfer D.P., Colacicco G., Sohr R., Lang F., Hellweg R., and Lang U.E. Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdale. Cell. Physiol. Biochem. 22 (2008) 735-744
3. Agid Y.G., Buzsaki D.M., Diamond R., Frackowiak J., Giedd J., Girault J.A., Grace A., Lambert J.J.M., Mayberg H., Popoli M., Prochiantz A., Richter-Levin G., Somogyi P., Spedding M., Svenningsson P., and Weinberger D. How can drug discovery for psychiatric disorders be improved?. Nat. Rev. 6 (2007) 189-201
4. Al-Damluji S. The mechanism of action of antidepressants: a unitary hypothesis based on transport-p. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 201-216
5. Altar C.A., Vawter M.P., and Ginsberg S.D. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 34 (2009) 18-54
6. Bachmann R.F., Schloesser R.J., Gould T.D., and Manji H.K. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol. Neurobiol. 32 (2005) 173-202
7. Banko J.L., Merhav M., Stern E., Sonenberg N., Rosenblum K., and Klann E. Behavioral alterations in mice lacking the translation repressor 4E-BP2. Neurobiol. Learn. Mem. 87 (2007) 248-256
8. Bayés A., and Grant S.G. Neuroproteomics: understanding the molecular organization and complexity of the brain. Nat. Rev. Neurosci. 10 (2009) 635-646
9. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., and Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6 (2006) 3414-3425
10. Beaulieu J.M., Marion S., Rodriquiz R.M., Medvedev I.O., Sotnikova T.D., Ghisi V., Wetsel W.C., Lefkowitz R.J., Gainetdinov R.R., and Caron M.G. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132 (2008) 125-136
11. Borsini F., Podhorna J., and Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology 163 (2002) 121-141
12. Bourin M., and Hascoet M. Drug mechanisms in anxiety. Curr. Opin. Investig. Drugs 2 (2001) 259-265
13. Bourin M., Petit-Demoulière B., Dhonnchadha B.N., and Hascöet M. Animal models of anxiety in mice. Fundam. Clin. Pharmacol. 21 (2007) 567-574
14. Brown S.L., Charney D.S., Woods S.W., Heninger G.R., and Tallman J. Lymphocyte beta-adrenergic receptor binding in panic disorder. Psychopharmacology (Berlin) 94 (1988) 24-28
15. Cabral A., Ross J.D., Castilho V.M., Brandao M.L., and Nobre M.J. Glutamate receptor antagonism in inferior colliculus attenuates elevated startle response of high anxiety diazepam-withdrawn rats. Neuroscience 161 (2009) 707-717
16. Carboni L., Piubelli C., Pozzato C., Astner H., Arban R., Righetti P.G., Hamdan M., and Domenici E. Proteomic analysis of rat hippocampus after repeated psychosocial stress. Neuroscience 137 (2006) 1237-1246
17. Carboni L., Vighini M., Piubelli C., Castelletti L., Milli A., and Domenici E. Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists. Eur. Neuropsychopharmacol. 16 (2006) 521-537
18. Carroll M., Dyer J., and Sossin W.S. Serotonin increases phosphorylation of synaptic 4EBP through TOR, but eukaryotic initiation factor 4E levels do not limit somatic cap-dependent translation in aplysia neurons. Mol. Cell. Biol. 26 (2006) 8586-8598
19. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., Myers R.M., Bunney Jr. W.E., Akil H., Watson S.J., and Jones E.G. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15653-15658
20. Covault J., Pettinati H., Moak D., Mueller T., and Kranzler H.R. Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 127B (2004) 42-47
21. De Berardis D., Conti C.M., Campanella D., Carano A., Di Giuseppe B., Valchera A., Tancredi L., Serroni N., Pizzorno A.M., Fulcheri M., Gambi F., Sepede G., Moschetta F.S., Salerno R.M., and Ferro F.M. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J. Biol. Regul. Homeost. Agents 22 (2008) 195-200
22. Desrumaux C., Risold P.Y., Schroeder H., Deckert V., Masson D., Athias A., Laplanche H., Le Guern N., Blache D., Jiang X.C., Tall A.R., Desor D., and Lagrost L. Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. FASEB 19 (2005) 296-297
23. Ditzen C., Jastorff A.M., Kessler M.S., Bunck M., Teplytska L., Erhardt A., Krömer S.A., Varadarajulu J., Targosz B.S., Sayan-Ayata E.F., Holsboer F., Landgraf R., and Turck C.W. Protein biomarkers in a mouse model of extremes in trait anxiety. Mol. Cell Proteomics 5 (2006) 1914-1920
24. Ditzen C., Varadarajulu J., Czibere L., Gonik M., Targosz B.S., and Hambsch B. Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways. Mol. Psychiatry (2009) 1-10 (2009 Jan 13)
25. Duman C.H., Schlesinger L., Russell D.S., and Duman R.S. Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res. 1199 (2008) 148-158
26. Ewing J.F., and Maines M.D. Regulation and expression of heme oxygenase enzymes in aged-rat brain: age related depression in HO-1 and HO-2 expression and altered stress-response. J. Neural Transm. 113 (2006) 439-454
27. Fernández E., Collins M.O., Uren R.T., Kopanitsa M.V., Komiyama N.H., Croning M.D.R., Zografos L., Armstrong J.D., Choudhary J.S., and Grant S.G.N. Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol. Sys. Biol. 5 (2009) 1-17
28. Fowler V.M. Capping actin filament growth: tropomodulin in muscle and nonmuscle cells. Soc. Gen. Physiol. Ser. 52 (1997) 79-89
29. Garcia-Garcia A.L., Elizalde N., Matrov D., Harro J., Wojcik S.M., Venzala E., Ramirey M.J., Del Rio J., and Tordera R.M. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol. Psychiatry 66 (2009) 275-282
30. Garner M., Möhler H., Stein D.J., Mueggler T., and Baldwin D.S. Research in anxiety disorders: from the bench to the bedside. Eur. Neuropsychopharmacol. 19 (2009) 381-390
31. Gisler S.M., Kittanakom S., Fuster D., Wong V., Bertic M., Radanovic T., Hall R.A., Murer H., Biber J., Markovich D., Moe O.W., and Stagljar I. Monitoring protein-protein interactions between the mammalian integral membrane transporters and PDZ-interacting partners using a modified split-ubiquitin membrane yeast two-hybrid system. Mol. Cell. Prot. 7 (2008) 1362-1377
32. Graeff F.G., Guimaraes F.S., De Andrade T.G.C.S., and Deakin J.F.W. Role of 5-HT in stress, anxiety and depression. Pharmacol. Biochem. Behav. 54 (1996) 129-141
33. Hahn C., Banerjee A., MacDonald M.L., Cho D., Kamins J., Nie Z., Borgmann-Winter K.E., Grosser T., Pizarro A., Ciccimaro E., Arnold S.E., Wang H., and Blair I.A. The post-synaptic density of human postmortem brain tissues: an experimental study paradigm for neuropsychiatric illnesses. PlosOne 4 (2009) e5251
34. Handley S.L., and McBlane J.W. 5-HT drugs in animal models of anxiety. Psychopharmacology (Berlin) 112 (1993) 13-20
35. Holtmaat A., and Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat. Rev. Neurosci. 10 (2009) 647-658
36. Hovatta I., Tennant R.S., Helton R., Marr R.A., Singer O., Redwine J.M., Ellison J.A., Schadt E.E., Verma I.M., Lockhart D.J., and Barlow C. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 438 (2005) 662-666
37. Huang S.Y., Lin W.W., Ko H.C., Lee J.F., Wang T.J., Chou Y.H., Yin S.J., and Lu R.B. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol. Clin. Exp. Res. 28 (2004) 374-384
38. Ikegaya Y., Yamada M., Fukuda T., Kuroyanagi H., Shirasawa T., and Nishiyama N. Aberrant synaptic transmission in the hippocampal CA3 region and cognitive deterioration in protein-repair enzyme-deficient mice. Hippocampus 11 (2001) 287-298
39. Johnson P.L., Truitt W.A., Fitz S.D., Lowry C.A., and Shekhar A. Neural pathways underlying lactate-induced panic. Neuropsychopharmacology 33 (2008) 2093-2107
40. Johnston-Wilson N.L., Sims C.D., Hofmann J.P., Anderson L., Shore A.D., Torrey E.F., and Yolken R.H. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatr. 5 (2000) 142-149
41. Kalueff A.V., and Murphy D.L. The importance of cognitive phenotypes in experimental modeling of animal anxiety and depression. Neural Plast. 2007 (2007) 52087
42. Khawaja X., Xu J., Liang J.J., and Barrett J.E. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J. Neurosci. Res. 75 (2004) 451-460
43. King J.S., Teo R., Ryves J., Reddy J.V., Peters O., Orabi B., Hoeller O., Williams R.S., and Harwood A.J. The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells. Dis. Model Mech. 2 (2009) 306-312
44. Kishida K.T., and Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid. Redox Signal. 9 (2007) 233-244
45. Krömer S.A., Kessler M.S., Milfay D., Birg I.N., Bunck M., Czibere L., Panhuysen M., Pütz B., Deussing J.M., Holsboer F., Landgraf R., and Turck C.W. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J. Neurosci. 25 (2005) 4375-4384
46. Lange S.S., Mitchell D.L., and Vasquez K.M. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10320-10325
47. Lowry C.A., Hale M.W., Evans A.K., Heerkens J., Staub D.R., Gasser P.J., and Shekhar A. Serotoninergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann. N. Y. Acad. Sci. 1148 (2008) 86-94
48. Martinowich K., Manji H., and Lu B. New insights into BDNF function in depression and anxiety. Nat. Neurosci. 10 (2007) 1089-1093
49. Matigian N., Windus L., Smith H., Filippich C., Pantelis C., McGrath J., Mowry B., and Hayward N. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signaling pathway. Mol. Psychiatry 12 (2007) 815-825
50. Miller A.L. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern. Med. Rev. 13 (2008) 216-226
51. Miller D.B., and O'Callaghan J.P. Depression, cytokines, and glial function. Metabolism 54 (2005) 33-38
52. Najima Y., Yahagi N., Takeuchi Y., Matsuzaka T., Sekiya M., Nakagawa Y., Amemiya-Kudo M., Okazaki H., Okazaki S., Tamura Y., IIzuka Y., Ohashi K., Harada K., Gotoda T., Nagai R., Kadowaki T., Ishibashi S., Yamada N., Osuga J., and Shimano H. High mobility group protein-B1 interacts with sterol regulatory element-binding proteins to enhance their DNA binding. J. Biol. Chem. 280 (2005) 27523-27532
53. Nakatani N., Ohnishi T., Iwamoto K., Watanabe A., Iwayama Y., Yamashita S., Ishitsuka Y., Moriyama K., Nakajima M., Tatebayashi Y., Akiyama H., Higuchi T., Kato T., and Yoshikawa T. Expression analysis of actin-related genes as an underlying mechanism for mood disorders. Biochem. Biophys. Res. Commun. 352 (2007) 780-786
54. Nishikawa H., Inoue T., Masui T., Izumi T., Nakagawa S., and Koyama T. Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: involvement of cytochrome P450 3A4. Psychiatry Clin. Neurosci. 62 (2008) 591-596
55. Otomo M., Takahashi K., Miyoshi H., Osada K., Nakashima H., and Yamaguchi N. Some selective serotonin reuptake inhibitors inhibit dynamin I guanosine triphosphatase (GTPase). Biol. Pharm. Bull. 31 (2008) 1489-1495
56. Pawlak R., Magarinos A., Melchor J., McEwen B., and Strickland S. Tissue plasminogen activator in the amygdale is critical for stress-induced anxiety-like behavior. Nat. Neurosci. 6 (2003) 168-174
57. Pollak D., Weitzdoerfer R., Yang Y.W., Prast H., Hoeger H., and Lubec G. Cerebellar protein expression in three different mouse strains and their relevance for motor performance. Neurochem. Int. 46 (2005) 19-29
58. Scoles D.R. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim. Biophys. Acta 1785 (2008) 32-54
59. Shevchenko A., Wilm M., Vorm O., and Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68 (1996) 850-858
60. Skelton M.R., Ponniah S., Wang D.Z., Doetschman T., Vorhees C.V., and Pallen C.J. Protein tyrosine phosphatase alpha (PTP alpha) knockout mice show deficits in Morris water maze learning, decreased locomotor activity, and decreases in anxiety. Brain Res. 984 (2003) 1-10
61. Sousa N., Lukoyanov N.V., Madeira M.D., Almeida O.F.X., and Paula-Barbosa. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience 97 (2000) 253-266
62. Sünram-Lea S.I., Dewhurst S.A., and Foster J.K. The effect of glucose administration on the recollection and familiarity components of recognition memory. Biol. Psychol. 77 (2008) 69-75
63. Thöny B., Auerbach G., and Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 347 Pt 1 (2000) 1-16
64. Tohda C., Nakanishi R., and Kadowaki M. Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase. Brain Dev. 31 (2009) 69-74
65. Toro C., and Deakin J.F. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr. Res. 80 (2005) 323-330
66. Tsaluchidu S., Cocchi M., Tonello L., and Puri B.K. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry 8 Suppl. 1 (2008) S5
67. Tyeryar K.R., and Undie A.S. Tandem regulation of phosphoinositide signaling and acute behavioral effects induced by antidepressant agents in rats. Psychopharmacology (Berlin) 193 (2007) 271-282
68. Tyeryar K.R., Vongtau H.O., and Undieh A.S. Diverse antidepressants increase CDP-diacylglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain. BMC Neurosci. 24 (2008) 9-12
69. Uys J.D., Stein D.J., and Daniels W.M. Neuroproteomics: relevance to anxiety disorders. Curr. Psychiatry Rep. 8 (2006) 286-290
70. van Zundert B., Yoshii A., and Constantine-Paton M. Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal. Trends Neurosci. 27 (2004) 428-437
71. Wand G. The anxious amygdala: CREB signaling and predisposition to anxiety and alcoholism. J. Clin. Invest. 115 (2005) 2697-2699
72. Weder H.G. The interaction of central acting drugs with glutamate dehydrogenase. Arzneimittelforschung 28 (1978) 752-755
73. Wu L.J., Kim S.S., and Zhuo M. Molecular targets of anxiety: from membrane to nucleus. Neurochem. Res. 33 (2008) 1925-1932
74. Zarate Jr. C.A., Singh J., and Manji H.K. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 59 (2006) 1006-1020